Incorporation and priming function of trnalys in hiv and related viruses
OwnerLawrence Kleiman, Shan Cheninventors
Life of this patent
Estimating the term…
Loading patent…
OwnerLawrence Kleiman, Shan Cheninventors
Estimating the term…
The present invention relates to the demonstration of a direct relationship between the amount of tRNALys3 packaged into HIV, the amount of tRNALys3 placed onto the reverse transcriptase primer binding site which can initiate reverse transcription, and viral infectivity. The present invention also relates to the incorporation of lysyl tRNA synthase into HIV-1 and to the aminoacylation status of tRNALys3 and its impact on virion incorporation. The present invention also relates to methods of modulating lysyl tRNA synthetase (LysRS)-facilitated processes associated with tRNALys3 priming function of RT, to bioassays to screen and identify compounds which interfere with these processes and to compositions for modulating these processes. In one particular embodiment, the compositions modulate the incorporation of LysRS and/or tRNALys3 into HIV and related virions. The present invention also relates to aaRS-facilitated processes associated with their cognate tRNAaa priming function in other types of retroviruses and to methods, assays and compositions which modulate them.
A method of modulating the incorporation of a tRNA involved in reverse transcriptase (RT) priming into a retroviral virion, comprising a modulation of the activity and/or of the level of a cognate aminoacyl tRNA synthetase, wherein the level and/or activity of said cognate aminoacyl tRNA synthetase in a cell infected by said retrovirus positively correlates with an incorporation of said tRNA into said virion.
A method of targeting a molecule into a retrovirus virion comprising providing said molecule linked to a sufficient number of aminoacyl tRNA synthetase involved in transporting its cognate tRNA into a retroviral vi don of said retrovirus in a cell infected with said retrovirus, whereby incorporation of said aminoacyl tRNA synthetase into said virion enables incorporation of said molecule thereinto.
A chimeric protein capable of being incorporated into HIV or SIV virions, comprising a first and second portion, wherein said first portion comprises a sufficient number of amino acids of an intermediate form of LysRS to enable incorporation of said chimeric protein into said virions.
A molecule for interfering with incorporation of a native tRNA involved in reverse transcriptase (RT) priming and/or of its native cognate aminoacyl tRNA synthetase into a retroviral virion, wherein said molecule is expressed in trans with respect to the retroviral genome and comprises one of:
A method of screening and selecting an agent that modulates the incorporation of a tRNA and/or a cognate aminoacyl tRNA synthetase thereof into a retroviral virion comprising:
A method for reducing the infectivity of a retrovirus, comprising a reduction in the incorporation of a tRNA involved in RT priming and/or of the cognate aminoacyl tRNA synthetase thereof.
A method of modulating an aminoacyl tRNA synthetase-facilitated process associated with its cognate tRNA priming function of reverse transcriptase (RT) wherein this process is selected from the group consisting of a) cognate tRNA incorporation into the retrovirus virion;
A method of screening and selecting an agent that modulates the incorporation of a tRNA and/or a cognate aminoacyl tRNA synthetase thereof into a retroviral virion comprising:
Dependencies are inferred from the claim text.